Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in breast cancer patients.
The aim of this study was to examine the prognostic significance of carbonic anhydrase IX (CA-IX), an endogenous marker for tumor hypoxia; endoglin (CD105), a proliferation-associated and hypoxia-inducible glycoprotein and 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidative DNA lesion, in breast cancer patients. Immunohistochemical expressions of CA-IX, CD105 and 8-OHdG, analyzed on paraffin-embedded tumor tissues from forty female breast cancer patients, were used to assess their prognostic implication on overall survival (OS) and relapse-free survival (RFS). Patients with high CA-IX expression (above cut-off value) had a higher occurrence of relapse (P = = 0.002). High CA-IX expression was significantly associated with shorter RFS (P < 0.001, hazard ratio (HR) 0.21) and shorter OS (P < 0.001, HR 0.19). Lymph node negative patients with high CA-IX expression had worse RFS (P = 0.031, HR 0.14) and OS (P = 0.005, HR 0.05). Patients with grade I&II tumors and high CA-IX expression showed shorter RFS (P = 0.028, HR 0.28) and OS (P = 0.008, HR 0.20). Worse OS (P = 0.046, HR 0.28) was found in subgroup of patients with grade II tumors and high CA-IX expression. Among all three markers, only high CA-IX expression was strong independent prognostic indicator for shorter OS (HR 4.14, 95% CI 1.28-13.35, P = 0.018) and shorter RFS (HR 3.99, 95% CI 1.38-11.59, P = 0.011). Elevated expression of CA-IX was an independent prognostic factor for decreased RFS and OS and a significant marker for tumor aggressiveness. CD105 had week prognostic value; whereas, 8-OHdG, in this study, did not provide sufficient evidence as a prognostic indicator in breast cancer patients.
Department of Radiation Oncology, University of Zagreb, University Hospital for Tumors, Zagreb, Croatia. lidija.beketic.oreskovic@zg.t-com.hr
Lidija
L
Beketic-Oreskovic
Petar
P
Ozretic
Zahid N
ZN
Rabbani
Isabel L
IL
Jackson
Bozena
B
Sarcevic
Sonja
S
Levanat
Petra
P
Maric
Ivan
I
Babic
Zeljko
Z
Vujaskovic
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000378:metabolism*; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000378:metabolism; D000071063:Endoglin; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000378:metabolism*; D015996:Survival Rate; D046888:Tissue Array Analysis
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface; D000080242:8-Hydroxy-2'-Deoxyguanosine; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases; D003849:Deoxyguanosine
J Clin Oncol. 2001 Aug 15;19(16):3660-8
11504747
Br J Cancer. 1984 Jun;49(6):709-15
6733019
Cancer Res. 1997 Jul 15;57(14):2827-31
9230182
Br J Cancer. 2003 Jul 21;89(2):271-6
12865916
Gynecol Oncol. 2010 Mar;116(3):452-8
19913895
Cell Death Differ. 2008 Apr;15(4):660-6
18219320
Carcinogenesis. 2000 Mar;21(3):361-70
10688856
Histopathology. 1991 Nov;19(5):403-10
1757079
Leuk Res. 2000 Jun;24(6):461-8
10781678
Nature. 1992 Oct 29;359(6398):843-5
1279431
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9
9223322
Eur J Cancer. 1996 Jun;32A(7):1209-14
8758255
Eur J Cancer. 2006 Oct;42(15):2653-9
16996262
Arch Pathol Lab Med. 2000 Jul;124(7):966-78
10888772
J Biol Chem. 2003 Aug 1;278(31):29184-91
12754217
Breast Cancer Res Treat. 2003 Sep;81(2):137-47
14572156
Clin Chim Acta. 2004 Jan;339(1-2):1-9
14687888
Cancer Res. 1999 Nov 15;59(22):5830-5
10582706
Clin Cancer Res. 2004 Dec 1;10(23):7925-33
15585626
Adv Exp Med Biol. 1983;159:487-95
6416031
Semin Oncol. 1988 Apr;15(2 Suppl 1):20-5
3285482
Nat Rev Cancer. 2002 Jan;2(1):38-47
11902584
Cancer Lett. 1995 Apr 14;90(2):157-62
7736451
Cancer Res. 2000 Mar 1;60(5):1442-8
10728711
Br J Cancer. 2007 Jan 15;96(1):104-9
17213826
J Biol Chem. 2000 Aug 18;275(33):25130-8
10833514
Cancer Res. 1999 Feb 15;59(4):856-61
10029075
J Clin Oncol. 1989 Mar;7(3):355-66
2918331
Cancer Res. 1991 Jun 15;51(12):3316-22
2040005
Cancer Res. 1997 Jun 15;57(12):2362-5
9192809
Cancer Res. 2001 Nov 1;61(21):7992-8
11691824
J Pathol. 1996 Apr;178(4):363-6
8691311
Cancer. 1986 Dec 15;58(12):2662-70
3536070
J Investig Med. 2009 Aug;57(6):720-3
19494787
Cancer. 1983 Nov 1;52(9):1551-7
6352003
Annu Rev Med. 1993;44:201-10
8476242
Br J Cancer. 1999 Feb;79(5-6):991-5
10070902
J Cell Biochem. 2009 Aug 15;107(6):1053-62
19479945
Mutat Res. 2007 Jul 10;631(1):62-8
17512776
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Cancer Res. 2001 Dec 15;61(24):8924-9
11751418
Br J Cancer. 1997;75(3):311-8
9020473
J Cell Physiol. 2001 Jul;188(1):1-7
11382917
Am J Clin Pathol. 2003 Mar;119(3):374-80
12645339
J Clin Pathol. 2005 Feb;58(2):172-7
15677538
Lung Cancer. 2005 Sep;49(3):325-35
15935515
Cancer Res. 2000 Dec 15;60(24):7075-83
11156414
Clin Cancer Res. 2002 Aug;8(8):2595-604
12171890
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
11181773
Cancer Res. 2001 Sep 1;61(17):6394-9
11522632